Hims & Hers Health stock rally: Key levels to watch

Traders Union
All News
Stocks
Hims & Hers Health up 2.6% today

Highlights

Hims & Hers Health expanded into Australia, offering GLP-1 weight-loss drugs and new men's health treatments via its Pilot platform.
The move increases the company's addressable market and diversifies revenue streams outside the United States.
Shares of Hims & Hers Health advanced 2.6% to $29.58 with technical signals indicating short-term downside pressure and a projected 2 to 3 day range of $27.82 to $31.34.

Australian market entry expands product reach, fueling positive investor reaction

Hims & Hers Health Inc is expanding its portfolio by offering branded GLP-1 weight-loss medications and additional men's health treatments in Australia through its Pilot platform, according to Investing.com. This launch broadens the company's product reach into a new region, creating fresh opportunities for demand growth and diversifying revenue streams. As the company enters the Australian market, investors have responded positively to this new addressable market and the strategic enhancement of the product lineup.

Mixed momentum and resistance at $30.26 shape technical outlook

On the technical front, HIMS is trading below the MA-20 and MA-50 on the hourly chart while maintaining position above the MA-200 as measured on the daily timeframe. The Ichimoku Kijun level at $30.26 is acting as immediate resistance. Intraday momentum is negative, with MACD registering a strong sell, ADX flat, and RSI weak at 45.9. Stochastic RSI is overbought, CCI is neutral, and Bull/Bear Power remains strongly positive, indicating buyers' dominance despite mixed momentum signals. Awesome Oscillator stays neutral, highlighting prevailing directional uncertainty.

Volatility expected as range-bound action limits directional conviction

Short-term price action for HIMS is expected to remain volatile, with a projected range over the next 2 to 3 trading days between $27.82 and $31.34. Probability-based models suggest a 68% chance of further downside and a 32% chance of an upward move, with a baseline scenario forecasting continued sideways movement within this range. A clear break above $30.26 would open a bullish scenario, while a drop below the lower end of the range could trigger further weakness.

Viktoras Karapetjanc, Traders Union expert, sees the recent expansion of Hims & Hers Health into the Australian market as a constructive step that aligns with strong demand trends in healthcare innovation. He believes the launch of GLP-1 medications and men's treatments significantly increases the company’s addressable market and supports investor optimism. While recent price action suggests some technical headwinds, macro and fundamental drivers remain supportive. "If HIMS can break above $30.26 and sustain momentum, I expect continued upside as long as investor confidence holds."

Earlier, analysts noted that Hims & Hers Health was experiencing short-term technical weakness despite a fundamentally positive outlook. The current analysis adds a new dimension by highlighting fresh product launches and international expansion, with traders advised to closely monitor the $30.26 resistance level as a potential inflection point for price direction.

Source of Data: HIMS Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.